21-Jul-2009 - Biogen Inc.

Asuragen Signs Agreement with Biogen Idec to Pursue Companion Diagnostic Strategy

Asuragen, Inc. announced that it has entered into an agreement with Biogen Idec to identify a potential companion diagnostic test that may be used to select patients likely to respond to a Biogen Idec therapeutic candidate in clinical development.

“The integrated drug-diagnostic co-development strategy being pursued by Biogen Idec and Asuragen has enormous potential to help physicians identify patients that will benefit from specific cancer treatments, and will be another step towards delivering on the promise of personalized medicine,” said Matt Winkler, CEO of Asuragen. “We look forward to leveraging our long history and broad expertise in biomarker discovery, pharmacogenomic services, and diagnostic development capabilities for this project.”

Facts, background information, dossiers
  • Asuragen
  • Biogen Idec
  • Winkler
  • services
  • medicine
  • diagnostic tests
More about Biogen
  • News

    Siemens and Biogen cooperate

    Siemens Healthineers and Biogen announced that the companies plan to jointly develop magnetic resonance imaging (MRI) applications with the intent of quantifying key markers of multiple sclerosis (MS) disease activity and progression. Siemens Healthineers aims to enable healthcare providers ... more

More about Asuragen